From The Foundry, an Incubator Focused on Ophthalmology
Executive Summary
The Foundry has created a new incubator to focus on ophthalmology, Forsight Labs, in partnership with Eugene de Juan, MD, a leading ophthalmologist and serial entrepreneur, who was one of the founders of Second Sight, and InnoRx.
You may also be interested in...
In Glaucoma, Devices Go Eye-to-Eye with Drugs
Glaucoma is of serious interest to VCs and strategic investors because of its sheer size; the disease affects 3 million people, most of them managed by drugs. Glaucoma drugs have created a $4 billion market, but have several problems, the greatest of which is non-compliance. Glaukos and other device companies aim to introduce devices that are safe and efficacious enough to compete directly with drugs, rather than standing in as an alternative to today's glaucoma surgeries reserved for end-stage patients. Glaukos recently marked a first of its kind victory; with a tiny implantable ophthalmic stent, Glaukos emerged from a PMA clinical trial that convinced an FDA panel of the benefit-to-risk ratio of its approach when used as a first-line therapy in a select group.
Device Incubation: Challenges in Making the Model Work
Device incubators have their proponents and detractors, but remain a constant source of company creation. The big question: is this model sustainable?
Device Incubation: Challenges in Making the Model Work
Device incubators have their proponents and detractors, but remain a constant source of company creation. The big question: is this model sustainable?